“`html

Women’s ‍Health Headlines: September 2025 Recap

September 2025⁢ brought a wave of crucial updates ‍that continue to shape the care of women⁣ across all stages of life.

In ⁤the ever-evolving field of obstetrics and gynecology, noteworthy advancements emerged in maternal-fetal medicine, reproductive endocrinology, oncology, and more.

In⁣ this monthly recap, Contemporary ⁢OB/GYN highlights ⁤the most impactful regulatory news, clinical research findings, and expert perspectives from september 2025.

Click on each title⁤ below for in-depth coverage of these key updates.

Hyperemesis Gravidarum and ⁣Mental Health⁤ Risks

Hyperemesis gravidarum (HG) is associated with substantially increased risks of neuropsychiatric and ‍mental health disorders, according to a retrospective cohort study of 476,857 pregnant women using data from the TriNetX Global⁤ Collaborative Network across 18 countries.researchers identified⁣ over a 50% increased risk for 13 outcomes, including postpartum psychosis, PTSD, and a twofold higher risk of Wernicke’s encephalopathy, eating disorders, and depression. Postpartum depression was especially elevated, with a⁣ 2.7-fold increased risk. Outcomes did not differ by HG severity ⁣based on metabolic disturbance, suggesting all patients ⁢with HG warrant early mental health support. Investigators emphasized the need for ⁣integrated care addressing both physical and psychiatric risks in‍ affected patients.

Elinzanetant for Vasomotor Symptoms

Elinzanetant significantly‍ reduced vasomotor symptoms (VMS) in postmenopausal women,⁢ according to results of the phase 3 OASIS-3 trial published in⁢ JAMA Internal Medicine. Among 628 participants randomized to elinzanetant 120 mg or placebo for 52 weeks, elinzanetant ⁢achieved a 73.8% reduction in moderate ‍to severe hot flashes and night‍ sweats by week 12 compared with 47% in the placebo group. benefits included improved sleep and menopause-specific quality-of-life.